A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin and Metformin Fixed Dose Combination, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes Mellitus
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Alogliptin/metformin (Primary) ; Alogliptin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 28 Sep 2016 Results published in the Takeda Media Release
- 28 Sep 2016 According to a company media release, Takeda has obtained the New Drug Application Approval from the Ministry of Health, Labour and Welfare for the Inisync Combination Tablets, a fixed-dose combination of Nesina and metformin hydrochloride for the treatment of type 2 diabetes, based on the results of this and other trials (see profile 250740).
- 08 Dec 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.